KGI initiates coverage on iX Biopharma with ‘Outperform’ and target price of $1.17

The 12-month target price of $1.17, which is based on sum-of-the-parts valuation, implies a 120.8% upside from the last close of 53 cents.

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.theedgesingapore.com)